← Back to Pharma Solutions
Pharma · Therapeutic area

Rare & Autoimmune

Autoimmune Disease

Non-invasive biomarkers, peer-reviewed and procedure-free.

For autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis and related cholangiopathies, Perspectum's biomarkers replace diagnostic ERCP and serial biopsy wherever the science allows. MRCP+ is the imaging endpoint of choice in three current PSC trials.

The point: keep the diagnostic insight; remove the procedural patient burden.

3 current PSC programmes0 procedural complications

Other therapeutic areas

Ready to see what your programme could look like with quantitative imaging at the centre?

Talk to our pharma services team. We'll come back with a brief outlining trial design implications and a confidential proposal within five working days.

Concept · Pharma · Send feedback